**APPENDIX: ADDITIONAL TABLE**

**Table A.1: Treatment sequences**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **MTX-IR subpopulation** | | | | |
|  | **Scenario I** | | **Scenario II** | |
|  | **Treatment** | **Comparator** | **Treatment** | **Comparator** |
| 1st Line | Methotrexate | Methotrexate | Methotrexate | Methotrexate |
| 2nd Line | Tofacitinib | Etanercept | Tofacitinib | Adalimumab |
| 3rd Line | Adalimumab | Adalimumab | Etanercept | Etanercept |
| 4th Line | Abatacept | Abatacept | Abatacept | Abatacept |
| 5th Line | Tocilizumab | Tocilizumab | Tocilizumab | Tocilizumab |
| 6th Line | Rituximab | Rituximab | Rituximab | Rituximab |
| 7th Line | Salvage therapy | Salvage therapy | Salvage therapy | Salvage therapy |
| **TNFi-IR subpopulation** | | | | |
|  | **Scenario III** | | **Scenario IV** | |
|  | **Treatment** | **Comparator** | **Treatment** | **Comparator** |
| 1st Line | Methotrexate | Methotrexate | Methotrexate | Methotrexate |
| 2nd Line | Etanercept | Etanercept | Etanercept | Etanercept |
| 3rd Line | Tofacitinib | Adalimumab | Tofacitinib | Abatacept |
| 4th Line | Abatacept | Abatacept | Tocilizumab | Tocilizumab |
| 5th Line | Tocilizumab | Tocilizumab | Rituximab | Rituximab |
| 6th Line | Rituximab | Rituximab | Salvage therapy | Salvage therapy |
| 7th Line | Salvage therapy | Salvage therapy | - | - |

**Table caption:** Table A.1 presents the treatment sequences modelled in the analysis. In each scenario, the treatment sequence is compared with the comparator sequence. Sequences were modelled from the point of convergence. All treatments are administered in combination with methotrexate.

Abbreviations. MTX-IR: methotrexate inadequate responder. TNFi-IR: inadequate responder to tumor necrosis factor inhibitor.